3D Cancer Cell Culture Systems for Dormant Cell Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer therapies focus on killing primary tumors or detectable tumors at distant sites, but they fail to effectively target and disable dormant disseminated tumor cells, micrometastatic cancer cells, and suppressed cancer cells that can cause recurrence.
Innovation Solution
The use of in vitro systems that mimic real-life 3D conditions, such as those provided by Basement Membrane Extract (BME) and Porcine small intestine submucosa gel (SISgel), to culture cancer cells and identify candidate therapeutic agents that can selectively target and inhibit the growth or proliferation of dormant cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current cancer therapies target primary tumors or detectable tumors, then tumor killing effectiveness is improved, but dormant disseminated tumor cells and micrometastatic cancer cells remain untreated and can cause recurrence
Solution Approach 1:
The patent applies preliminary action by targeting and disabling dormant disseminated tumor cells and micrometastatic cancer cells before they proliferate and become detectable. The therapy intervenes in the pre-proliferation stage, preventing the harmful effect of recurrence before it occurs, rather than waiting for tumor detection and then treating.
2Ease of manufacture
If 2D tissue culture systems are used to screen cancer drugs, then experimental simplicity is improved, but the ability to model true physiological conditions and dormant cell behavior is worsened
Solution Approach 1:
The patent transitions from 2D tissue culture systems to 3D organoid culture systems. This dimensional change enables the modeling of true physiological conditions, including the dormant state of cancer cells in their natural three-dimensional microenvironment, thereby improving measurement precision while maintaining experimental feasibility.
Solution Approach 2:
The patent changes the cultural parameters from 2D monolayer conditions to 3D organoid conditions, including modifications in spatial arrangement, extracellular matrix composition, and nutrient diffusion patterns. These parameter changes enable the system to accurately model dormant cell behavior and microenvironmental interactions that are impossible to capture in 2D systems.
3Productivity
If conventional cancer drugs are used to treat detectable tumors, then proliferating tumor growth is inhibited, but dormant cells remain unaffected and treatment duration is limited by toxicities
Solution Approach 1:
The therapy performs preliminary disabling of dormant cells before they become problematic, allowing for longer treatment duration without being limited by the appearance of detectable tumors or severe toxicities. By preventing rather than treating, the therapy can be administered more sustainably.
Data Source
AI summary
Methods for screening therapeutic agents for activity against dormant cancer cells, therapeutic agents identified by the methods, and treatment methods related to the same, and methods for screening therapeutic agents for activity against microscopic metastatic tumor cancer cells, therapeutic agents identified by the methods, and treatment methods related to the same.